AstraZeneca’s Soriot Keeps His Options Open When It Comes To Sanofi
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Soriot declined to say whether or not he is considering taking over the top spot at rival Sanofi during a media briefing, doing nothing to end speculation he might be a contender to succeed Viehbacher.
You may also be interested in...
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.